Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Other Rheumatic Conditions

Expert Q&A: Dr. Michael Lockshin on APS

Richard Quinn  |  November 13, 2015

Michael Lockshin, MD, reminds medical professionals that patients suffering from antiphospholipid syndrome (APS) don’t respond to medications in the same way as patients with other clotting-related diseases. Insufficient evidence exists to determine whether the new wave of anticoagulant medications is safe for use in patients with APS…

Early Probiotics Supplementation Tied to Lower Risk of Islet Autoimmunity

Will Boggs, MD  |  November 12, 2015

NEW YORK (Reuters Health)—Exposure to probiotics in the first few weeks of life is associated with a reduced risk of islet autoimmunity, according to results from the TEDDY study. “Early supplementation of probiotics may be important but we need more research on this,” Dr. Ulla Uusitalo from University of South Florida in Tampa told Reuters…

Bariatric Surgery Tied to Improvement in Psoriasis, Psoriatic Arthritis

Megan Brooks  |  November 11, 2015

NEW YORK (Reuters Health)—Obese patients with psoriasis or psoriatic arthritis are apt to experience significant symptomatic relief following bariatric surgery, according to a new chart review. Specifically, the study found that more than half of the patients with psoriasis or psoriatic arthritis reported improvements in their disease following surgery. Dr. Soumya Reddy, assistant professor of…

Helicobacter & Campylobacter May Play Roles in IBD

Reuters Staff  |  November 9, 2015

NEW YORK (Reuters Health)—Helicobacter and Campylobacter species appear to play opposing roles in inflammatory bowel disease (IBD), according to a systematic review and meta-analysis. The prevalence of IBD has increased steadily in the face of falling H. pylori infection rates, suggesting a negative association, whereas some studies have suggested that some Campylobacter species are involved…

Genetic Data Suggest Dividing IBD into 3 Forms

Will Boggs, MD  |  November 2, 2015

NEW YORK (Reuters Health)—Data from a genetic association study suggest that inflammatory bowel disease (IBD) should be divided into a three-group continuum, rather than the current division between Crohn’s disease and ulcerative colitis. “The current clinical classifications of IBD, while important and useful, are a simplification of the true biological variation of this disease,” Dr….

Rectosigmoidoscopy vs. Colonoscopy for Assessing Ulcerative Colitis Activity

Reuters Health  |  October 30, 2015

NEW YORK (Reuters Health)—In most cases, rectosigmoidoscopy and colonoscopy assessments of disease activity in ulcerative colitis yield the same results, researchers report. “In clinical practice, rectosigmoidoscopy is enough to assess endoscopic activity and endoscopic healing,” Dr. Jean-FrĂ©dĂ©ric Colombel from Icahn School of Medicine at Mount Sinai, N.Y., told Reuters Health by email. Dr. Colombel and…

Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis

Will Boggs, MD  |  October 15, 2015

NEW YORK (Reuters Health)—The human IgG1 anti-TNF antibody adalimumab is safe and effective for short- and long-term treatment, and the calcineurin inhibitor tacrolimus given short-term brings remission, in patients with refractory ulcerative colitis, according to two new studies in the Journal of Crohn’s and Colitis. In the first study, online Sept. 21, Dr. Tamas Molnar…

Dr. Yokoyama, MD, with Jennifer Laurent

Interdisciplinary Collaboration at Wash U Advances Understanding of Immunology, Rheumatology

Gretchen Henkel  |  October 14, 2015

In June 2014, 10 members of a church group returned to St. Louis from Haiti, where they had contracted chikungunya virus (CHIKV), a mosquito-transmitted alphavirus previously unknown in the Western hemisphere that produces inflammatory arthritis symptoms. Because CHIKV-related arthritis mimics seronegative RA, a group of clinicians, immunologists, virologists and geneticists at the Washington University in…

FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning

Michele B. Kaufman, PharmD, CGP, RPh  |  October 14, 2015

The U.S. Food and Drug Administration (FDA) has toughened the existing warnings for nonsteroidal anti-inflammatory drugs (NSAIDs) due to their stroke and myocardial infarction (MI) risk increase.1 Due to a continual review of these products, FDA is requiring label updates for all prescription NSAIDs. Over-the-counter (OTC) NSAIDs already list the increased risk of MI and…

Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA

Michele B. Kaufman, PharmD, BCGP  |  October 14, 2015

In a global Phase 3 trial, subcutaneous secukinumab proved safe and effective in patients with psoriatic arthritis. Also, a version of aspartyl-alanyl diketopiperazine, a biologic for knee OA, has entered Phase 3 trials…

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 35
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences